Atea Pharmaceuticals Accumulated Retained Earnings Deficit Trend from 2010 to 2021

AVIR -  USA Stock  

USD 26.23  0.90  3.32%

Atea Pharmaceuticals Accumulated Retained Earnings Deficit yearly trend continues to be relatively stable with very little volatility. Accumulated Retained Earnings Deficit are likely to drop to -70,304,211. During the period from 2010 to 2021, Atea Pharmaceuticals Accumulated Retained Earnings Deficit destribution of quarterly values had r-value of (0.75) from its regression line and mean deviation of  8,642,526. As of 09/18/2021, Direct Expenses is likely to grow to about 1.4 M.

Search Historical Trends 

 
Refresh
Check Atea Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Atea Pharmaceuticals main balance sheet or income statement drivers, such as Direct Expenses of 1.4 M, Gross Profit of 43.5 M or Operating Expenses of 47.6 M, as well as many exotic indicators such as Long Term Debt to Equity of 0.0077, PPandE Turnover of 42.93 or Receivables Turnover of 13.11. Atea Pharmaceuticals financial statements analysis is a perfect complement when working with Atea Pharmaceuticals Valuation or Volatility modules. It can also supplement various Atea Pharmaceuticals Technical models. Please continue to the analysis of Atea Pharmaceuticals Correlation against competitors.

Atea Pharmaceuticals Accumulated Retained Earnings Deficit Breakdown

Showing smoothed Accumulated Retained Earnings Deficit of Atea Pharmaceuticals with missing and latest data points interpolated. A component of Shareholders Equity representing the cumulative amount of the entities undistributed earnings or deficit. May only be reported annually by certain companies; rather than quarterly.Atea Pharmaceuticals' Accumulated Retained Earnings Deficit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Atea Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Accumulated Retained Earnings Deficit10 Years Trend
Decreasing
Slightly volatile
 Accumulated Retained Earnings Deficit 
Share
      Timeline 

Atea Pharmaceuticals Accumulated Retained Earnings Deficit Regression Statistics

Arithmetic Mean(45,940,684)
Geometric Mean 44,935,354
Coefficient Of Variation(23.94)
Mean Deviation 8,642,526
Median(40,179,000)
Standard Deviation 10,996,560
Range 30,125,211
R-Value(0.75)
R-Squared 0.56
Significance 0.00494
Slope(2,288,267)

Atea Pharmaceuticals Accumulated Retained Earnings Deficit History

2019-54.2 M
2020-65.2 M
2021-70.3 M

About Atea Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Atea Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Atea Pharmaceuticals investors use historical funamental indicators, such as Atea Pharmaceuticals's Accumulated Retained Earnings Deficit, to determine how well the company is positioned to perform in the future. Although Atea Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Atea Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Atea Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Atea Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Atea Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2021
Accumulated Retained Earnings Deficit-65.2 M-70.3 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA-10.9 M-11.8 M
Earnings before Tax-10.9 M-11.8 M
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts. Atea Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Atea Pharmaceuticals without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Cryptocurrency Center Now

   

Cryptocurrency Center

Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
All  Next Launch Module

Pair Trading with Atea Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atea Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atea Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Atea Pharmaceuticals Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Atea Pharmaceuticals and Equillium. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Please continue to the analysis of Atea Pharmaceuticals Correlation against competitors. Note that the Atea Pharmaceuticals information on this page should be used as a complementary analysis to other Atea Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Complementary Tools for Atea Pharmaceuticals Stock analysis

When running Atea Pharmaceuticals price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Equity Search
Search for activelly traded equities including funds and ETFs from over 30 global markets
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
The market value of Atea Pharmaceuticals is measured differently than its book value, which is the value of Atea Pharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Atea Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Atea Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atea Pharmaceuticals' market value can be influenced by many factors that don't directly affect Atea Pharmaceuticals underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atea Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Atea Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atea Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.